Future Oncology

Article	Citations
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation	129
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811	109
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer	109
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma withFGFR2rearrangements	95
Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities	72
An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer	69
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)	69
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA	67
The abscopal effect of radiation therapy	63
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma	63
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma	60
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial	59
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy	59
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer	58
How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancer	56
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia	52
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma	50
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design	49
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC	46
Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing	44
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study	44
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer	44
Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis	42
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer	41
Organ tropism in solid tumor metastasis: an updated review	40

The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors	40
Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma	39
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer	39
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)	38
Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials	38
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies	37
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412	36
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma	36
CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies	35
Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey	34
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma	34
GammaTile®: Surgically targeted radiation therapy for glioblastomas	33
Clinicopathological study of organ metastasis in endometrial cancer	32
Systemic therapy of advanced hepatocellular carcinoma	32
Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma	31
MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic	30
Oncolytic viruses: challenges and considerations in an evolving clinical landscape	29
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer	28
Molecular avenues in targeted doxorubicin cancer therapy	28
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design	28
INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance	28
Teleoncology or telemedicine for oncology patients during the COVID-19 pandemic: the new normal for breast cancer survivors?	27
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma	27
Dostarlimab in the treatment of recurrent or primary advanced endometrial cancer	27
Cancer and COVID-19: analysis of patient outcomes	27
A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma	26
Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy	26
Current trends in the treatment of HR+/HER2+ breast cancer	26
GALNT14 regulates ferroptosis and apoptosis of ovarian cancer through the EGFR/mTOR pathway	25
Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials	25
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer	25
Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis	25
Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma	24
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design	24
Prognostic value of lymphocyte-to-monocyte ratio and systemic immune-inflammation index in non-small-cell lung cancer patients with brain metastases	24
Oral health-related quality of life in oral cancer patients: systematic review and meta-analysis	24
How we treat Merkel cell carcinoma: within and beyond current guidelines	23
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design	23
Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test	23
Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?	23
Precision oncology: a clinical and patient perspective	23
ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT)	23
A theoretical model of financial burden after cancer diagnosis	22
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases	22
Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor	22
The Lebanese Society of Medical Oncology (LSMO) statement on the care of patients with cancer during the COVID-19 pandemic	22
Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination	22
Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study	22
Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303	22
The future of radiation-induced abscopal response: beyond conventional radiotherapy approaches	22

RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer	21
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design	21
KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer	21
Surgery for pancreatic cancer: current controversies and challenges	21
DNA damage response alterations in gastric cancer: knocking down a new wall	20
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial	20
First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: a real-world analysis	20
Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life	20
The psychological challenges for oncological patients in times of COVID-19 pandemic: telemedicine, a solution?	20
Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress	20
EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma	20
Long noncoding RNA ANRIL as a novel biomarker in human cancer	20
Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 – what’s old is new again?	19
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma	19
Revisiting the role of TRAIL/TRAIL-R in cancer biology and therapy	19
Understanding patient factors to increase uptake of cancer screening: a review	19
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer	19
Granulomatous prostatitis: a challenging differential diagnosis to take into consideration	18
What is the alternative? Responding strategically to cancer misinformation	18
Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma	18
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis	18
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design	18
Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA	18
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia	18
Addressing resistance to immune checkpoint inhibitor therapy: an urgent unmet need	17
Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives	17
Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic	17
Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas	17
The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer	17
Trastuzumab deruxtecan for HER2+ advanced breast cancer	17
KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer	17
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma	17
EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations	16
KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer	16
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study	16
Current and potential biomarkers in gastric cancer: a critical review of the literature	16
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review	16
Circulating serum exosomal miR-92a-3p as a novel biomarker for early diagnosis of gastric cancer	16
Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer	16
Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study	16
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer	15
Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer	15
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors	15
Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design	15
The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment	15
Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes	15
Expression profiles and prognostic roles of m6A writers, erasers and readers in gastric cancer	15
CD38 as an immunomodulator in cancer	14
What the oncologist needs to know about COVID-19 infection in cancer patients	14
Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer	14
Molecular tests and target therapies in oncology: recommendations from the Italian workshop	14
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design	14
Clinical sequelae of the novel coronavirus: does COVID-19 infection predispose patients to cancer?	14
Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer	14
A nomogram for predicting overall survival in patients with uterine leiomyosarcoma: a SEER population-based study	14
Improvement strategies for successful next-generation sequencing analysis of lung cancer	14
Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses	14
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma	14
Prognostic value of systemic inflammatory marker in patients with head and neck squamous cell carcinoma undergoing surgical resection	14
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer	14
Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia	14
Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol	14
Cancer-associated fibroblasts of colorectal cancer and their markers: updates, challenges and translational outlook	13
Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas	13
Discovering the first US FDA-approved computer-aided polyp detection system	13
Patient satisfaction with telemedicine for prechemotherapy evaluation during the COVID-19 pandemic	13
Predictive markers of immune response in glioblastoma: hopes and facts	13
Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia	13
Metastatic lymph node ratio as a better prognostic tool than the TNM system in colorectal cancer	13
Healthcare utilization and total costs of care among patients with advanced metastatic gastric and esophageal cancer	13
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma	13
Pulmonary nodules precision localization techniques	13
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer	13
Immuno-oncology for esophageal cancer	13
Lurbinectedin in the treatment of relapsed small cell lung cancer	13
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review	13
NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)	13
Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma	13
A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer	13
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication	13

Financial toxicity and its impact on health outcomes and caregiver burden among adult cancer survivors in the USA	12
Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice	12
Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences	12
Excellent diagnostic performance of FNA-Tg in detecting lymph nodes metastases from papillary thyroid cancer	12
FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer	12
Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index	12
Upregulated expression of MTFR2 as a novel biomarker predicts poor prognosis in hepatocellular carcinoma by bioinformatics analysis	12
Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study	12
Prognostic implications of depression and inflammation in patients with metastatic lung cancer	12
Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS	12
Development and validation of nomograms for epithelial ovarian cancer: a SEER population-based, real-world study	12
Real-world genetic testing patterns in metastatic castration-resistant prostate cancer	12
Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data	12
Multimodal analysis of ctDNA methylation and fragmentomic profiles enhances detection of nonmetastatic colorectal cancer	12
Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial	12
Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis	12
Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?	12
Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma	12
Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA	12
Hematopoietic stem cell transplantation dilemma during the COVID-19 era	12
A call to action: Antiracist patient engagement in adolescent and young adult oncology research and advocacy	12
Pattern of breast cancer presentation during the COVID-19 pandemic: results from a cohort study in the UK	12
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis	12
A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas	12
Treatment patterns and clinical outcomes of palbociclib-based therapy received in US community oncology practices	11
Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma	11
Treatment patterns in patients with metastatic non-small-cell lung cancer in the era of immunotherapy	11
Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma	11
Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan	11
Pragmatic patient engagement in designing pragmatic oncology clinical trials	11
How we treat HR-positive, HER2-negative early breast cancer	11
Use of real-world evidence for oncology clinical decision making in emerging economies	11
B-cell epitope peptide cancer vaccines: a new paradigm for combination immunotherapies with novel checkpoint peptide vaccine	11
PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion	11
Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia	11
Phase I study protocol: NKTR-255 as monotherapy or combined with daratumumab or rituximab in hematologic malignancies	11
The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma	11
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma	11
Implementing multidisciplinary tumor boards in oncology: a narrative review	11
Copanlisib in the treatment of non-Hodgkin lymphoma	11
Serum exosomal miR-377-3p and miR-381-3p as diagnostic biomarkers in colorectal cancer	11
Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy	11
ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1	11
Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC	11
Acute myeloid leukemia transformed to a targetable disease	11
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)	11
Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis	10
POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer	10
Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review	10
Single agent VS-6766 or VS-6766 plus defactinib inKRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial	10
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis	10
Rituximab biosimilars in hematologic malignancies: the need for a real-world approach	10
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma	10
The impact of the coronavirus pandemic on the management of cancer patients in Lebanon: a single institutional experience	10
Real-world disease burden and outcomes of brain metastases in EGFR mutation-positive non-small-cell lung cancer	10
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma	10
Predicting occult lymph node metastasis by nomogram in patients with lung adenocarcinoma ≤2 cm	10
Nanotechnology-based platforms to improve immune checkpoint blockade efficacy in cancer therapy	10
Real-world effectiveness outcomes in patients diagnosed with metastatic triple-negative breast cancer	10
Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges	10
PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer	10
Impact of corona-phobia on attitudes and acceptance towards COVID-19 vaccine among cancer patients: a single-center study	10
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib	10
Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma	10
Telehealth amid the COVID-19 pandemic: perception among Asian, Native Hawaiian and Pacific Islander cancer patients	10
Patient engagement in cancer research from the patient's perspective	10
CaboPoint: a phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma	10
Real-world use and acceptance of rituximab biosimilars in non-Hodgkin lymphoma in an oncologist network in Germany	9
Sacituzumab govitecan: past, present and future of a new antibody–drug conjugate and future horizon	9
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer	9
TRIM58 is a prognostic biomarker remodeling the tumor microenvironment in KRAS-driven lung adenocarcinoma	9
Plasma exosomalmiR-1260a, miR-7977andmiR-192-5pas diagnostic biomarkers in epithelial ovarian cancer	9
Serum level of long noncoding RNA B3GALT5-AS1 as a diagnostic biomarker of colorectal cancer	9
2022 cancer statistics: Focus on lung cancer	9
Plain Language Summary of Publication articles: helping disseminate published scientific articles to patients	9
Real-world clinical outcomes with first-line avelumab in locally advanced/metastatic Merkel cell carcinoma in the USA: SPEAR-Merkel	9
Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors	9
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer	9
Bidirectional deep neural networks to integrate RNA and DNA data for predicting outcome for patients with hepatocellular carcinoma	9
Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials	9
Treatment and relapse in breast cancer show significant correlations to noninvasive testing using urinary and plasma DNA	9
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations	9
Anti-angiogenic role of microRNA-23b in melanoma by disturbing NF-κB signaling pathway via targeted inhibition of NAMPT	9
Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer	9
Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma	9
Encorafenib plus binimetinib in patients withBRAFV600-mutant non-small cell lung cancer: phase II PHAROS study design	9
Prognostic significance of baseline neutrophil–lymphocyte ratio in patients with non-small-cell lung cancer: a pooled analysis of open phase III clinical trial data	9
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma	9
Momelotinib for the treatment of myelofibrosis with anemia	9
Analysis of differential metabolites in lung cancer patients based on metabolomics and bioinformatics	9
The future of cancer research after COVID-19 pandemic: recession?	9
Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland and Spain	9
Cancer stem cells, epigenetics, tumor microenvironment and future therapeutics in cutaneous malignant melanoma: a review	9
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients	9
Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study	9